Novel Strategies for Treating Castration-Resistant Prostate Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 162
Editors
Interests: oncogenes; drug combinations; biomarkers; chemoprevention; small-molecule inhibitors
Special Issues, Collections and Topics in MDPI journals
Interests: triple-negative breast cancers; hormone-receptor-positive breast cancers; drug resistance; dormancy; metastasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer (PCa) remains the leading cause of cancer-related mortality among men worldwide, despite significant advances in clinical management. The initial systemic treatment for metastatic prostate cancer primarily involves two key components: androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) therapy. Additionally, docetaxel chemotherapy together with prednisone is the recognized standard of care for individuals with metastatic disease.
However, treatment options become limited for patients who experience docetaxel failure, often requiring reliance on alternative therapies such as cabazitaxel or enrollment in clinical trials investigating novel agents. Recent research has identified new approaches for managing metastatic castration-resistant prostate cancer (mCRPC), particularly following disease progression after docetaxel therapy. Despite these advances, castration resistance inevitably develops over time.
Currently, approved pharmacological treatments for mCRPC include tubulin-targeting taxanes, DNA damage-inducing radioligand therapies and poly(ADP)-ribose polymerase inhibitors (PARPIs). These treatments are especially helpful for patients with homologous recombination repair-deficient (HRD) tumors. These emerging treatments encompass innovative approaches alongside traditional modalities like radiotherapy, the inhibition of oncogenic signaling via alternative pathways and the activation of the immune system to promote an antitumor response. However, castration-resistant prostate cancer is still uncurable and accounts for nearly all prostate cancer-related deaths. Although options exist, the median overall survival for males with mCRPC remains under five years, indicating an urgent necessity for novel therapeutic strategies. This Special Issue will highlight innovative treatment strategies for CRPC, encompassing both basic and preclinical research that advance our understanding of how to target and treat it.
Dr. Balaji Chandrasekaran
Dr. Eswar Shankar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- androgen receptor
- CRPC
- drug resistance
- combination therapy
- small molecules
- chemoprevention
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
